SEC Info - Revance Therapeutics, Inc. - ‘S-8’ on 2/28/22

SEC Info℠

Home

My Interests

Help

Please Sign In

Revance Therapeutics, Inc. – ‘S-8’ on 2/28/22 – ‘EX-23.1’

On: Monday, 2/28/22, at 5:06pm ET · Effective: 2/28/22 · Accession #: 1479290-22-36 · File #: 333-263099

Previous ‘S-8’: ‘S-8’ on 1/29/21 · Next: ‘S-8’ on 2/28/23 · Latest: ‘S-8’ on 2/29/24 · 26 References:

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/28/22  Revance Therapeutics, Inc.        S-8         2/28/22    5:197K

Registration Statement – Securities for an Employee Benefit Plan — Form S-8 — SA’33

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML     50K 
                Employee Benefit Plan                                            
 3: EX-5.1      Opinion of Counsel re: Legality                     HTML     10K 
 4: EX-23.1     Consent of Expert or Counsel                        HTML      6K 
 2: EX-FILING FEES  Filing Fees                                     HTML     14K 
 5: EX-99.2     Miscellaneous Exhibit                               HTML     44K

‘EX-23.1’ — Consent of Expert or Counsel

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

<! C: C:

Document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of Revance Therapeutics, Inc. of our report dated February 28, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in Revance Therapeutics, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2021.

/s/ PricewaterhouseCoopers LLP

San Jose, California

February 28, 2022

Dates Referenced Herein and Documents Incorporated by Reference

This ‘S-8’ Filing	Date	Other Filings

Filed on / Effective on:	2/28/22	10-K, 8-K
	12/31/21	10-K, 4, DEF 14A
		List all Filings

5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/29/24  Revance Therapeutics, Inc.        S-8         2/29/24    4:123K
 2/28/24  Revance Therapeutics, Inc.        10-K       12/31/23  110:12M
 2/28/23  Revance Therapeutics, Inc.        S-8         2/28/23    5:192K
 2/28/23  Revance Therapeutics, Inc.        10-K       12/31/22  109:14M
 5/10/22  Revance Therapeutics, Inc.        10-Q        3/31/22   82:9M                                     Donnelley … Solutions/FA

21 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/22  Revance Therapeutics, Inc.        10-K       12/31/21  106:12M
 2/28/22  Revance Therapeutics, Inc.        8-K:2,5,9   2/25/22   11:353K
 2/07/22  Revance Therapeutics, Inc.        8-K:5       2/02/22   10:172K
 1/18/22  Revance Therapeutics, Inc.        8-K:8       1/14/22   10:163K
12/22/21  Revance Therapeutics, Inc.        8-K:5,9    12/17/21   11:385K
 5/07/21  Revance Therapeutics, Inc.        8-K:5,9     5/05/21   13:192K
 2/25/21  Revance Therapeutics, Inc.        10-K       12/31/20  109:12M
 1/29/21  Revance Therapeutics, Inc.        S-8         1/29/21    3:137K
 2/14/20  Revance Therapeutics, Inc.        8-K:1,2,3,8 2/11/20   14:1.4M                                   Donnelley … Solutions/FA
 1/21/20  Revance Therapeutics, Inc.        S-8         1/21/20    3:141K
 2/28/19  Revance Therapeutics, Inc.        S-8         2/28/19    3:143K
 3/02/18  Revance Therapeutics, Inc.        S-8         3/02/18    3:126K
 2/28/17  Revance Therapeutics, Inc.        S-8         2/28/17    3:116K
 3/04/16  Revance Therapeutics, Inc.        S-8         3/04/16    3:155K
11/10/15  Revance Therapeutics, Inc.        10-Q        9/30/15   66:5.6M
 4/03/15  Revance Therapeutics, Inc.        S-8         4/03/15    3:150K                                   Workiva Inc Wde… FA01/FA
 2/14/14  Revance Therapeutics, Inc.        S-8         2/14/14    3:91K                                    Donnelley … Solutions/FA
 2/11/14  Revance Therapeutics, Inc.        8-K:5,9     2/11/14    2:49K                                    Donnelley … Solutions/FA
 2/04/14  Revance Therapeutics, Inc.        8-A12B                 1:14K                                    Donnelley … Solutions/FA
 2/03/14  Revance Therapeutics, Inc.        S-1/A                  5:4.8M                                   Donnelley … Solutions/FA
 1/27/14  Revance Therapeutics, Inc.        S-1/A¶                22:5.2M                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001479290-22-000036 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)